Skip to main content

Table 1 Characteristic of selected studies in the meta-analysis

From: Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysis

Author Year/country Gender Tumor stage Antibody Dilution Follow up Quality
(M/F) source Score
Wang et al 2014/China 25/27 TNM Maixin NA 40 mo 8
Yang et al 2010/China 33/25 Duke Santa Cruz 1:50 5 yrs 8
Pap et al 2009/Romania 71/46 Duke Fremont 1:50 NA 8
Hashimoto et al 2008/USA 79/52 TNM Serotec 1: 100 38 mo 9
Qi et al 2008/China 33/19 Duke Maixin NA NA 7
Feng et al 2007/China 20/11 TNM Zhongshan 1:75 NA 8
Lundin et al 2005/Finland 118/119 Duke Serotec 1:100 116 mo 9
Zhou et al 2005/China 33/19 Duke Zhongshan NA NA 7
Zuo et al 2004/China 29/22 Duke Zhongshan NA NA 7
Fujiya et al 2001/Japan 65/40 TNM Santa Cruz 1:50 10 yrs 9